Shopping Cart
- Remove All
Your shopping cart is currently empty
Ascrinvacumab
🥰Excellent
Catalog No. T76858Cas No. 1463459-96-2
Alias PF-03446962
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).
Ascrinvacumab
Ascrinvacumab
🥰Excellent
Purity: 98.18% (SEC-HPLC)
Catalog No. T76858Alias PF-03446962Cas No. 1463459-96-2
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $247 | In Stock | |
| 5 mg | $647 | In Stock | |
| 10 mg | $987 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Ascrinvacumab"
Hydrochlorothiazide
HCTZ
T144958-93-5
Hydrochlorothiazide (HCTZ) is a Thiazide Diuretic. The physiologic effect of hydrochlorothiazide is by means of Increased Diuresis.
- $29
Size
QTY
Alantolactone
Cited
Inula camphor, Helenine, helenin, Eupatal, Alant camphor, (+)-Alantolactone
T2896546-43-0
Alantolactone is a selective inhibitor of STAT3 that induces cancer-associated apoptosis and has antitumor activity.
- $50
Size
QTY
CitedGalunisertib
Cited
LY2157299
T2510700874-72-2
Galunisertib (LY2157299) is a TGF-β receptor type I (TGF-βRI) inhibitor (IC50=56 nM) that is selective. Galunisertib has antitumor activity and can be used in combination with PD-1 inhibitors.
- $40
Size
QTY
CitedA 83-01 Cited
ALK5 Inhibitor IV, A8301
T3031909910-43-6
A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.
- $52
Size
QTY
CitedCeritinib Cited
LDK378
T17911032900-25-6
Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.
- $45
Size
QTY
CitedPirfenidone Cited
S-7701,AMR-69, S-7701, AMR69
T238653179-13-8
Pirfenidone (AMR69) inhibits the production of CCL2 and CCL12 in fibroblasts and also decreases TGF-β2 protein levels. Pirfenidone is an antifibrotic agent that is commonly used in studies related to pulmonary fibrosis and also has anti-inflammatory activity.
- $30
Size
QTY
CitedCrizotinib Cited
PF-02341066
T1661877399-52-5
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.
- $46
Size
QTY
CitedEntrectinib Cited
RXDX-101, NMS-E628
T36781108743-60-7
Entrectinib (RXDX-101) is a Trk, ROS1, and ALK inhibitor that inhibits TrkA, TrkB, TrkC, ROS1, and ALK (IC50=1/3/5/12/7 nM) with oral activity and blood-brain-barrier penetration. Entrectinib exhibits both antitumor and CNS activity.
- $35
Size
QTY
CitedMonocrotaline Cited
Crotaline
T2803315-22-0
Monocrotaline (Crotaline) is a pyrrolizidine alkaloid extracted from the seeds of the Crotalaria plant. Monocrotaline has certain cellular activity against HepG2 cells and can induce pulmonary hypertension in rodents.
- $41
Size
QTY
CitedDMH-1 Cited
DMH1
T19421206711-16-1
DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.
- $53
Size
QTY
CitedBMP signaling agonist sb4 Cited
SB 4
T7799100874-08-6
BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)
- $39
Size
QTY
CitedChromenone 1
T613011639929-29-5In house
Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP). Chromenone 1 induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs.
- $70
Size
QTY
Select Batch
Concentration:9.31 mg/mL
Purity:98.18% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC). |
| Targets&IC50 | ALK1 (human):7 nM(Kd) |
| In vitro | Ascrinvacumab binds to human ALK1 with a Kd value of 7 nM[1]. In a 30-minute treatment, Ascrinvacumab blocks the response induced by BMP9 and FCS, alleviating BMP9-induced Smad1 phosphorylation intensity and duration[1]. At concentrations ranging from 0.01 to 10 μg/mL for 2 hours, Ascrinvacumab inhibits the binding of BMP9 to ALK1[1]. At 40 μg/mL for 2 hours, Ascrinvacumab effectively inhibits endothelial sprouting in human umbilical vein endothelial cells (HUVECs)[1]. |
| In vivo | In a mouse xenograft tumor model, the combination of Ascrinvacumab with bevacizumab (anti-VEGF) reduces human vascular density and enhances the anti-tumor efficacy[1]. |
| Alias | PF-03446962 |
| Molecular Weight | 150 kDa |
| Cas No. | 1463459-96-2 |
Storage & Solubility Information
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ascrinvacumab | purchase Ascrinvacumab | Ascrinvacumab cost | order Ascrinvacumab | Ascrinvacumab in vivo | Ascrinvacumab in vitro | Ascrinvacumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.